Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

European Commission Grants Orphan Drug Designation to Nana-val for Peripheral T-cell Lymphoma

September 8th 2022

The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir for use as a potential therapeutic option in patients with peripheral T-cell lymphoma.

Fixed-Duration Bendamustine/Rituximab Is Beneficial Irrespective of Mutation Status in Waldenström Macroglobulinemia

September 2nd 2022

Fixed-duration bendamustine plus rituximab was effective in patients with previously untreated Waldenström macroglobulinemia, regardless of MYD88L265P mutation status, but the presence of the CXCR4WHIM mutation may be associated with resistance to the combination.

Fixed-Duration Glofitamab Elicits Early, Durable Complete Remissions in Relapsed/Refractory LBCL

September 2nd 2022

Michael Dickinson, MBBS, expands on data from a phase 2 dose-expansion study of glofitamab in heavily pretreated, highly refractory large B-cell lymphoma, explains the effect bispecific antibodies could have on treatment, and highlights other research efforts surrounding glofitamab-based therapies.

CTCL Is Rare, Incurable, and Potentially Lethal in Advanced Stages

August 31st 2022

Although cutaneous T-cell lymphoma, a group of non-Hodgkin T-cell lymphomas, remains a rare disease, incidence has increased steadily since the 1970s.

Approval Sought for Tafasitamab/Lenalidomide Combo in R/R DLBCL in Hong Kong

August 31st 2022

The Hong Kong Special Administrative Region’s Department of Health has accepted for review a biologics license application seeking the approval of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Relma-cel Demonstrates Durable Activity in Relapsed/Refractory LBCL

August 22nd 2022

Relmacabtagene autoleucel elicited durable responses and a high overall survival rate in Chinese patients with relapsed/refractory large B-cell lymphoma, according to 2-year follow-up data from the phase 2 RELIANCE trial.

FDA Lifts Partial Clinical Hold on TakeAim Lymphoma Trial Evaluating Emavusertib in B-cell Malignancies

August 18th 2022

The FDA has lifted a partial clinical hold on the open-label, dose-escalating phase 1/2 TakeAim Lymphoma trial investigating the safety and efficacy of emavusertib in patients with relapsed or refractory B-cell malignancies.

Lenalidomide Plus Rituximab Represents Acceptable Chemo-Free Alternative for Untreated Advanced Follicular Lymphoma

August 18th 2022

The combination of lenalidomide and rituximab demonstrated durable safety and efficacy that was comparable to that achieved with rituximab plus chemotherapy in previously untreated patients with follicular lymphoma, according to 6-year data from the phase 3 RELEVANCE trial.

Anbalcabtagene Autoleucel Shows Promise in Relapsed/Refractory LBCL

August 17th 2022

Won Seog Kim, MD, PhD, discusses the potential clinical role of Anbalcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and the continued evolution of CAR T-cell therapy.

FDA Accepts sBLA for Polatuzumab Vedotin Plus R-CHP in Untreated DLBCL

August 16th 2022

The FDA has accepted a supplemental biologics license application for the combination of polatuzumab vedotin and R-CHP as a treatment for patients with previously untreated diffuse large B-cell lymphoma.

Subcutaneous Epcoritamab Plus R-DHAX/C Shows Promising Preliminary Activity in ASCT-Eligible, R/R DLBCL

August 15th 2022

Raul Cordoba, MD, PhD, discussed the efficacy and safety findings from cohort 4 of the EPCORE NHL-2 trial, the benefits observed with epcoritamab monotherapy in patients who did not proceed to transplant, and what the addition of epcoritamab to R-DHAX/C could mean for patients with relapsed/refractory DLBCL.

Dr. Michot on the Examination of CC-99282 in Relapsed/Refractory NHL

August 11th 2022

Jean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.

Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL

August 11th 2022

Single-agent tolinapant generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, according to data from the phase 2 ASTX660-01 trial.

CC-99282 Demonstrates Manageable Safety Profile, Elicits Favorable Responses in Non-Hodgkin Lymphoma

August 11th 2022

Jean-Marie Michot, MD, discusses the methods and rationale for the CC-99282-NHL-001 study.

Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCL

August 5th 2022

Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.

Dr. Brody on Second-Line CAR T-cell Therapy in DLBCL

July 22nd 2022

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Dr. D’Angelo on Emerging Therapies in DLBCL

July 21st 2022

Christopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.

FDA Grants Fast Track and Rare Pediatric Disease Designations to WU-CART-007 in R/R T-ALL and LBL

July 21st 2022

The FDA has granted fast track and rare pediatric disease designations to the CAR T-cell therapy WU-CART-007 for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

Multidisciplinary Team Approach Is Ideal for irAE Management in Follicular Lymphoma

July 21st 2022

Immune checkpoint inhibitor therapy in relapsed follicular lymphoma can induce immune-related adverse events which can be difficult to diagnose and manage.

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

July 20th 2022

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.